Literature DB >> 15122920

Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine.

Charbel E-H Moussa1, Christophe Wersinger, York Tomita, Anita Sidhu.   

Abstract

Parkinson's disease (PD) involves loss of dopaminergic neurons in the substantia nigra and is characterized by intracellular inclusions, Lewy bodies, consisting primarily of aggregated alpha-synuclein. Two substitution mutations (A53T and A30P) in alpha-synuclein gene have been identified in familial early-onset PD. To understand the biological changes that incur upon alpha-synuclein-induced cytotoxicity in the presence of dopamine, the current studies were undertaken. Human SH-SY5Y neuroblastoma cells coexpressing the human dopamine transporter [hDAT], and either wild type (wt) or mutant alpha-synucleins, were treated with 50 microM dopamine (DA). In cells expressing wt or A30P alpha-synuclein, DA accelerated production of reactive oxygen species and cell death as compared to cells expressing A53T or hDAT alone. The increased sensitivity of such cells to DA was investigated by measuring changes in cellular ionic gradient, by atomic absorption spectrometry, and cell metabolism, by high-resolution nuclear magnetic resonance spectroscopy. Both wt and A30P alpha-synuclein caused rapid decrease in levels of intracellular potassium, followed by mitochondrial damage and cytochrome c leakage, with decreased cellular metabolism as compared to cells expressing A53T or hDAT alone. Collapse of ionic gradient was significantly faster in A30P (t(1/2) = 3.5 h) than in wt (t(1/2) = 6.5 h) cells, and these changes in ionic gradient preceded cytochrome c leakage and depletion of metabolic energy. Neither wt nor mutant alpha-synuclein resulted in significant changes in ionic gradient or cellular metabolism in the absence of intracellular DA. These findings suggest a specific sequence of events triggered by dopamine and differentially exacerbated by alpha-synuclein and the A30P mutant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122920     DOI: 10.1021/bi036114f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  13 in total

Review 1.  Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.

Authors:  Orkid Coskuner-Weber; Vladimir N Uversky
Journal:  Int J Mol Sci       Date:  2018-01-24       Impact factor: 5.923

Review 2.  Alpha-synuclein and dopamine metabolism.

Authors:  Shun Yu; Kenji Uéda; Piu Chan
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

3.  Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins.

Authors:  Jihoon Kim; Masaki Kobayashi; Makoto Fukuda; Daisuke Ogasawara; Natsuki Kobayashi; Sungwoong Han; Chikashi Nakamura; Masaki Inada; Chisato Miyaura; Kazunori Ikebukuro; Koji Sode
Journal:  Prion       Date:  2010-01-04       Impact factor: 3.931

4.  The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein.

Authors:  Jihoon Kim; Ryuichi Harada; Masaki Kobayashi; Natsuki Kobayashi; Koji Sode
Journal:  Mol Neurodegener       Date:  2010-05-20       Impact factor: 14.195

5.  Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells.

Authors:  Marco Bisaglia; Elisa Greggio; Dragan Maric; David W Miller; Mark R Cookson; Luigi Bubacco
Journal:  BMC Neurosci       Date:  2010-03-25       Impact factor: 3.288

6.  Structures and free energy landscapes of the wild-type and A30P mutant-type α-synuclein proteins with dynamics.

Authors:  Olivia Wise-Scira; Ahmet Kemal Aloglu; Aquila Dunn; Isin Tuna Sakallioglu; Orkid Coskuner
Journal:  ACS Chem Neurosci       Date:  2013-01-30       Impact factor: 4.418

7.  Structures and free energy landscapes of the A53T mutant-type α-synuclein protein and impact of A53T mutation on the structures of the wild-type α-synuclein protein with dynamics.

Authors:  Orkid Coskuner; Olivia Wise-Scira
Journal:  ACS Chem Neurosci       Date:  2013-05-17       Impact factor: 4.418

8.  Mutant alpha-synuclein overexpression mediates early proinflammatory activity.

Authors:  Xiaomin Su; Howard J Federoff; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2009-04-28       Impact factor: 3.911

9.  Pharmacological profile of brain-derived neurotrophic factor (BDNF) splice variant translation using a novel drug screening assay: a "quantitative code".

Authors:  Valentina Vaghi; Alessio Polacchini; Gabriele Baj; Vera L M Pinheiro; Annalisa Vicario; Enrico Tongiorgi
Journal:  J Biol Chem       Date:  2014-07-29       Impact factor: 5.157

10.  Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity.

Authors:  Anna Moszczynska; Jumana Saleh; Hongyu Zhang; Brian Vukusic; Frank J S Lee; Fang Liu
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.